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Abstract: Two small leucine-rich proteoglycans (SLRP), decorin and biglycan, play important roles
in structural–functional integrity of the placenta and fetal membranes, and their alterations can
result in several pregnancy-associated diseases. In this review, we briefly discuss normal placental
structure and functions, define and classify SLRPs, and then focus on two SLRPs, decorin (DCN) and
biglycan (BGN). We discuss the consequences of deletions/mutations of DCN and BGN. We then
summarize DCN and BGN expression in the pregnant uterus, myometrium, decidua, placenta, and
fetal membranes. Actions of these SLRPs as ligands are then discussed in the context of multiple
binding partners in the extracellular matrix and cell surface (receptors), as well as their alterations
in pathological pregnancies, such as preeclampsia, fetal growth restriction, and preterm premature
rupture of membranes. Lastly, we raise some unanswered questions as food for thought.
Keywords: leucine-rich proteoglycans; decorin; biglycan; pregnancy; placenta; decidua; trophoblast;
trophoblast invasion; preeclampsia; fetal growth restriction; premature labor; premature preterm
rupture of membranes (PPROM); Ehlers–Danlos syndrome (EDS)
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1. A Brief Review of the Placental Structure and Functions

Stevenson and Nihar Ranjan Nayak

Placentas in eutherian mammals have evolved to nourish the embryo and the fetus.
For this function, they must invade the pregnant uterus to various degrees.
They can be broadly classified by their degree of invasiveness into the uterine endometrium: (i) “epitheliochorial” type (in ruminants), in which chorionic trophoblast cells
remain apposed to the uterine epithelium, without breaching it. There is evidence of a
certain degree of fusion between the trophoblast and the uterine epithelium. However,
in some regions such as chorionic girdles, trophoblast cells are highly invasive (e.g., in
horses); (ii) “endotheliochorial” type (in carnivores), in which the trophoblast invades the
uterine connective tissue to reach the maternal endothelium; (iii) “hemochorial” type (in
rodents, primates, and humans) in which trophoblast cells invade the maternal arteries to
derive oxygen and nutrients from the maternal arterial blood.
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Hemochorial placentas in different species display many similarities and differences
in the trophoblast cell types. Soares et al. (2017) reviewed their nomenclature, functions,
and molecular signatures in detail [1]. In the human placenta, maternal blood flow toward
the placenta for “hemotrophic” nutrition of the embryo is established at the end of the first
trimester. Until then, the nutrition of the embryo is “histotrophic”, derived from secretion
products (“uterine milk”) of the uterine glands [2,3]. Shortly following implantation at the
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early hemotrophic stage, the primitive syncytiotrophoblast invades the maternal vasculature, so that blood sinusoidal spaces appear in the sponge-like syncytium. Subsequently,
when chorionic villi are formed, bipotent stem cells contained within the cytotrophoblast
layer of the villi differentiate into two distinct pathways: the villous pathway, in which cells
proliferate and fuse, giving rise to the villous syncytiotrophoblast layer facing the maternal
sinusoids, engaged primarily in exchange and endocrine functions, and the extravillous
pathway in which cells break out of the villi as discrete cell columns which proliferate at
their base [4,5], migrate, and invade the decidua, endometrial glands, blood vessels, and
lymphatic vessels (Figure 1).

Figure 1. Adapted from [6] with permission. (A) Shortly after implantation (end of first week), stem cells of the trophectoderm give rise to the primitive syncytium (PS) by cell fusion. Lacunae (L) develop in the PS, as the precursor of the
intervillous space. Invasion of the PS into uterine glands allows “uterine milk” to fill up the lacunae (histotrophic nutrition).
Later, with invasion of the PS into uterine vessels (UV/UA), maternal blood fills the lacunae (hemotrophic nutrition).
Lymphatics (LL) are also invaded. (B) During the end of second week, proliferative cytotrophoblasts (CTBs) break through
the PS, forming primary villi. (C) During the third week, tertiary villi are formed by migration of the extraembryonic
mesoderm followed by vascularization. At distal sites, proliferative cell columns are formed which give rise to different
invasive extravillous trophoblast (EVT) subtypes. Interstitial cytotrophoblasts (iCTBs) migrate into the decidual stroma and
differentiate into placental bed giant cells (PBGCs). Endovascular trophoblasts migrate into spiral arteries and contribute to
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uterine natural killer (uNK) cell-initiated remodeling of spiral arteries (SA). Bulmer et al. (2020) [7] recently challenged the
long-held view that endovascular trophoblasts (eCTBs) replace the endothelium of spiral arteries during arterial remodeling.
By immunostaining a large number of chorionic villus biopsy samples, they found that, while sCTB plugs appear within
the arterial lumen, arteries were found with either missing or intact endothelium, but never lined by eCTBs. AE, amniotic
epithelium; CCT, cell column trophoblast; ESC, endometrial stromal cell; EB, embryoblast; EM, extraembryonic mesoderm;
eCTB, endovascular cytotrophoblast; PBGC, placental bed giant cell; ICM, inner cell mass, iCTB, interstitial cytotrophoblast;
LUE, luminal uterine epithelium; L, lacunae; LL lymphatic lumen; pF, placental fibroblast; PS, primitive syncytium; pV,
placental vessel; SA, spiral artery; S, syncytium; TE, trophectoderm; UG, uterine gland; uNK, uterine NK cell; UV, uterine
vein; UA, uterine artery; vCTB, villous cytotrophoblast.

1.2. Routes of Trophoblast Invasion
For many years, trophoblast invasion was believed to be restricted to uterine decidua
and the spiral arteries. This view was based on a variety of approaches including histology
of the evacuated early gestational placentas and placental bed biopsies. This explained
the connection of the arteries to the intervillous space of the placenta so that maternal
oxygenated arterial blood could flow to the placenta. However, this view has been revised
in recent years [8,9] evidenced by the findings of the presence of trophoblast cells in other
tubular structures, e.g., the uterine glands, veins, and lymphatics at different stages in
pregnancy. “Endoglandular invasion”, noted at the time of implantation, likely allows
“histotrophic” nutrition of the embryo with glandular secretion products (“uterine milk”)
prior to the establishment of “hemotrophic” nutrition. “Endo-venous invasion”, noted at all
gestational ages, guarantees the drainage of fluids from the placenta back into the maternal
circulation throughout pregnancy. In addition, “endolymphatic invasion” or invasion of
trophoblasts into the uterine lymph vessels (identified by lymphatic endothelium-specific
markers) has been visualized very early in gestation. This invasion may play a role in
regulating placental fluid pressure. At the end of the first trimester, endoarterial (commonly
described as endovascular) invasion of trophoblasts into spiral arteries takes place, enabling
hemotrophic nutrition. Furthermore, many extravillous trophoblast (EVT) cells remain
in the decidual extracellular matrix (ECM) as interstitial trophoblasts, some giving rise
to “placental bed giant cells” (PBGCs), which are believed to be noninvasive. PBGCs
have two distinct phenotypes [10]: polyploid single cells containing one or more nuclei
in a voluminous cytoplasm, and cell aggregates comprising mononuclear trophoblast
cells attached to one another by desmosomes, also having gap junctions (Connexin32 and
Connexin43). By contrast, gap junctions are absent in the polyploid single giant cells. It
remains unclear whether they arise by cell fusion or endomitosis or both. PBGCs are
immunoreactive for human placental lactogen (hPL) and human chorionic gonadotrophin
alpha chain (α-hCG) (Figure 1).
2. Proteoglycans
Proteoglycans (PGs) represent a structurally heterogeneous family of heavily glycosylated proteins that have undergone extensive post-translational modification with
sulfated sugar chains. Their protein cores are covalently attached to one or more (up to 100)
glycosaminoglycan (GAG) chains. Depending on their molecular size, they are arbitrarily
named as “small” or “large”. They are mostly located in the ECM, including the basement
membrane. Only one PG (serglycin) has been found to be intracellular, located most abundantly in the granules of mast cells. Another PG family, heparan sulfate proteoglycans, is
mostly associated with the cell surface (transmembrane or glycosylphosphatidylinositolanchored) or pericellular matrix comprising basement membranes (reviewed by Iozzo and
Schafer, 2015) [11]. As a major component of the ECM, PGs serve a variety of biological
functions. For example, they serve as storage sites for many growth factors, which are
shielded from circulating proteases against degradation. They can bind to other PGs or
fibrous matrix proteins such as collagen, to serve as a compression buffer against the stress
placed on the ECM. They can stabilize ligand–receptor interactions at the cell membrane,
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creating potentiated ternary signaling complexes that regulate multiple cellular functions
such as proliferation, migration, growth factor sensitivity, and adhesion to the ECM. They
can also independently activate various signaling cascades, attenuate the signaling of
growth factors, or regulate signaling from intracellular compartments. In contrast to classical ligand–receptor signaling, PG-mediated signaling is often characterized by ligand
promiscuity and low-affinity binding [11–14].
Small Leucine-Rich Proteoglycans
Small leucine-rich proteoglycans (SLRPs) are a class of PGs characterized by a relatively small protein core (as compared to the larger aggregating PGs) of 36–42 kDa and
encompassing a central region constituted by leucine-rich repeats (LRRs). The SLRPs are
ubiquitously expressed in most extracellular matrices and are highly expressed during
development in the thin membranes enveloping all the major organs such as meninges,
pericardium, pleura, periosteum, perichondrium, perimysium, and endomysium. This
strategic topology suggests that SLRPs are directly involved in regulating organ size and
shape during embryonic development. The 18 SLRP members are grouped into five classes:
Classes I–III are coded by canonical genes, whereas Classes IV and V are noncanonical
(Table 1 and Figure 2).
Table 1. A comprehensive classification of SLRPs.

Class

I

II

III

IV

V

Cys-Rich
Cluster
Consensus

Gene
Symbol

Eponym

Predominant
GAG

DCN

Decorin

DS *

BGN

Biglycan

#

ASPN

Asporin

ECM2

Extracellular
matrix protein 2

ECMX

ECM2-like protein,
X chromosome

FMOD

Fibromodulin

KS **

1q32.1

LUM

Lumican

KS **

12q21.33

PRELP

PRELP

KERA

Keratocan

KS **

OMD

Osteomodulin

KS **

CS

Chromosome
Location
12q21.33
Xq28

CX3 CX CX6 C

9q22.31
9q22.31
Xq28

CX3 CX CX9 C

1q32.1
12q21.33
9q22.31

#

EPYC

Epiphycan

OPTC

Opticin

OGN

Osteoglycin

9q22.31

CHAD

Chondroadherin

17q21.33

NYX

Nyctalopin

TSKU

Tsukushi

PODN

Podocan

PODNL1

Podocan like 1

DS */CS

12q21.33
CX2 CX CX6 C

CX3 CX CX6–17 C

1q32.1

Xp11.4
11q13.5

CX3–4 CX CX9 C

1p32.3
19p13.12

* Dermatan sulfate; # chondroitin sulfate; ** keratan sulfate. SLRPs are divided into five classes. Class I to III
are canonical SLRPs and IV and V are non-canonical. Table was modified from [11,15]. The consensus for the
N-terminal Cys-rich cluster is shown. where X represents any amino acid, while C represents a cysteine amino
acid. Predominant GAG and chromosomal location of the various SLRP genes is also shown.
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Figure 2. Chromosomal location and organization of various human SLRP classes. The chromosomal arrangement of the
various SLRP genes is shown in a telomeric orientation (right). Transcriptional direction is shown by the arrows. The
horizontal distance between genes is not to scale. The color-coded dendrogram shows the presence of five distinct families
of SLRP. Blue: Class I, orange: Class II, green: Class III, gray: Class IV, and yellow: Class V. This figure was modified and
adapted from [11,16].

SLRPs are ubiquitously expressed in the ECM of most tissues where they act as
structural constituents to maintain tissue architecture, and they are involved in range of
fundamental biological and pathophysiological functions, including collagen fibrillogenesis [17,18], signal transduction [19–21], and tumor-suppressor function [22,23]. SLRPs share
many biological functions by binding to ECM components, particularly various collagens,
receptor tyrosine kinases, and innate immune receptors (Toll-like receptors) on cell surfaces
when present in soluble form [11].
SLRPs are divided into five classes according to several characteristics such as structural and functional properties, homology at both the protein and the genomic level, the
presence of characteristic N-terminal Cys-rich clusters, and type of GAG chain [11,21,23,24]
(Table 1).
SLRPs are encoded by 18 distinct human genes. In the human, genes encoding SLRPs
are spread over seven chromosomes, with some genes clustered on chromosomes such as
chromosome 9 or 12 (Figure 2) [21]. At the protein level, SLRPs have a variable number of
LRRs comprising the major central domain. The arrangement of these LRRs in the central
domain forms a curved, solenoid structure with both convex and concave faces. A typical
SLRP consists of an N-terminus, containing four cysteine residues with a class-conserved
finite number of intervening amino acids [24,25]. The N-termini in different SLRPS are
variably modified to provide unique functions for each SLRP [26–28].
Within the conserved C-terminal cysteine-rich capping motif, a distinctive feature is
the presence of the recently described “ear repeat”. Typically, the ear repeats consist of
30 or more amino-acid residues including an atypical sequence of Cys located at about
10 residues after the asparagine residue in the consensus LRR [25]. This Cys capping
motif, designated LRRCE, is present in Classes I–III (canonical SLRPs), whereas classes
IV and V (non-canonical SLRPs) lack this [25]. The ear repeat is proposed to maintain the
conformation of the protein core and influence ligand-binding ability, and it is believed
to be a hallmark of true SLRP family. A genetic mutation at this position in the Decorin
(DCN) gene (Class I SLRP) leading to a truncated DCN protein core has been found in
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human congenital stromal corneal dystrophy [29,30]. Most SLRPs have both protein cores
and GAG chains. Class I–III SLRPs contain GAG chains with few exceptions, but the
noncanonical Class IV and V members lack GAG chains with the exception of 1 SLRP
(Chondroadherin). The GAGs of SLRPs are differentially processed in development and
aging, and they are variable with regard to size, number, sulfation, and epimerization in
different tissues.
Class I—This class contains the SLRP DCN, along with biglycan (BGN), asporin,
ECM2, and ECMX. The N termini consist of typical Cys residue clusters that form two
disulfide bonds. DCN and BGN contain chondroitin or dermatan sulfate GAG chains.
Asporin, although similar to DCN and BGN structurally, lacks the typical Ser–Gly dipeptide
and flanking amino acids required for glycanation [16]. Asporin is a member of the SLRP
gene cluster present on chromosome 9 with osteoadherin, osteoglycin, and ECM2. ECM2
and ECMX, although structurally different from conventional SLRPs, are 35% identical
to the LRR domains of DCN. Similar to asporin, both of them lack GAG chain and are
among the two poorly studied Class I SLRPs. ECM2 and ECMX are included in Class I
on the basis of genomic and protein homology, although very little is known about their
biological functions.
Class II—This class consists of five SLRPs divided into three subgroups on the basis
of protein homology. Fibromodulin and Lumican form subgroup A, subgroup B is made of
PRELP (proline/arginine-rich end leucine-rich repeat protein) and keratocan, and subgroup
C includes osteoadherin. This class contains primarily keratan sulfate and polylactosamine,
an unsulfated variant of keratan sulfate. Class II SLRPs have a similar exonic organization
(three exons), with the largest exon encoding most of LRRs.
Class III—This class contains three members: epiphycan, opticin, and osteoglycin. In
contrast to 10–12 LRRs present in other SLRP classes, the members of this class consist of
a low number of LRRs (seven LRRs) and seven exons. Epiphycan is the only dermatan
sulfate proteoglycan of this class.
Class IV—This noncanonical class of SLRPs consists of chondroadherin [31], nyctalopin [32,33], and a new member tsukushi [34], which has an expression pattern similar
to the shape of the Japanese horsetail plant tsukushi [34]. Nyctalopin was the first described glycosylphosphatidylinositol-anchored member and interestingly was linked to
the X chromosome similar to BGN, Class I SLRP. Both tsukushi and nyctalopin have
11 homologous LRRs flanked by an N-terminal Cys-rich region. Tsukushi shares functional
properties with class I SLRPs [35,36].
Class V—This is a new, little studied noncanonical class of SLRPs and contains two
genes, podocan [37] and a highly homologous podocan-like protein 1 (NCBI accession
number 079101). Podocan was originally cloned from a library derived from human immunodeficiency virus transgenic podocytes, giving rise to its eponym [37]. Although these
proteins have a different C-terminal Cys-rich cluster, they have 20 LRRs with homology to
class I and class II molecules.
Proteoglycan fragments: A number of proteoglycan fragments, including a 32mer IGD
peptide of aggrecan, G3 fragments of aggrecan and versican, a G1 containing N-terminal
fragment of versican (versikine), C-terminal LG1LG2LG3, LG1LG2, LG3, and endorepellin
fragments of perlecan domain V, C-terminal endostatin fragments of type XVIII collagen, a
biglycan fragment with transforming growth factor (TGF)-β inhibitory activity, lumican
fragments (lumcorin, lumikine), a decorin fragment (decorunt), and a link protein fragment
(linkN), have been described. These fragments have cryptic activities ranging from cell
proliferative to cell migratory, cell adhesive, cell differentiative, growth factor-like, matrix
metalloproteinase (MMP)-inhibitory, tissue repair effects, anabolic matrix stimulatory
properties, antiangiogenic properties, and effects on tissue fibrosis. These properties are
likely relevant to remodeling of the uterus during pregnancy, but their specific roles in
the uterus or the placenta have not been examined. For example, fragments of decorin,
biglycan, lumican, and keraotocan have been demonstrated in degenerating cartilages of
the human knee and hip joints [38]. As reviewed later, DCN peptides from the LLR-5
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domain were shown to be antiangiogenic and migration-inhibitory for trophoblast cells.
It remains to be investigated whether they appear in the maternal blood as predictive
biomarkers of preeclampsia (PE).
3. Distribution and Functions of DCN in the Pregnant Uterus and the Placenta
3.1. Cellular Source of DCN and Its Role in Trophoblast Functions
DCN is produced by a variety of stromal cells in the body such as fibroblasts in
the dermis, cornea, and chondrocytes of the cartilages [11]. In the pregnant uterus, it is
produced by endometrial stromal cells [39], decidual cells, and mesenchymal stromal cells
of the chorionic villi [40]. In the latter study, we found that DCN is colocalized with TGFβ
in the decidual ECM at various gestational ages. Since we previously showed that deciduaderived TGF-β provides a key control mechanism limiting trophoblast invasion [41], we
suggested that DCN in the decidual ECM serves as a storage device for TGF-β in an
inactive form, until cleaved and activated by the trophoblast-derived protease cascade
at the invasion front, to prevent over-invasion. Surprisingly, however, we found that
decidua-derived DCN, on its own, restrained human trophoblast proliferation, migration,
and invasiveness, independent of TGF-β [42]. These DCN actions were differentially
mediated by binding to multiple tyrosine kinase receptors epidermal growth factor receptor
(EGFR), insulin-like growth factor receptor (IGFR)-1, and vascular endothelial growth
factor receptor (VEGFR)-2 on the trophoblast cell surface [43]. Further studies revealed
that DCN binding to VEGFR-2 is abrogated with a VEGFR-2 blocking antibody, indicating
an overlap between the ligand-binding and the DCN-binding domains of VEGFR-2. DCN
binding had a 7–10-fold lower affinity than the VEGFR-2-specific ligand VEGF-E or native
ligand VEGF-A. Using DCN peptide fragments derived from the LRR 5 domain that
blocked DCN–VEGFR-2 interactions revealed that the VEGFR-2 binding site was confined
to a 12 amino-acid span of the LLR-5 domain of the DCN protein, overlapping with the
VEGF-binding site [44]. VEGFR-2 binding was found to be critical for DCN to restrain
VEGF-dependent migration and endovascular differentiation of the trophoblast, an event
essential for uterine arterial remodeling during normal pregnancy critical for adequate flow
of uterine arterial blood for fetal nourishment [45]. Indeed, mutating a single amino acid at
this binding site annulled VEGF-dependent DCN actions [46]. We further discovered that
selective DCN overproduction by decidual cells, but not villus mesenchymal cells, was
associated with PE with or without fetal growth restriction (FGR), and an elevated level of
maternal plasma DCN during the second trimester was a predictive biomarker of PE [47].
We established a cause–effect relationship between decidual DCN overproduction and
PE-associated phenotypes: impaired trophoblast invasion, endovascular differentiation,
and uterine angiogenesis [48]. Lastly, we discovered that DCN plays a restraining role
in human trophoblast stem cell self-renewal and differentiation into syncytiotrophoblast
(STB) and EVT [49]. The sources of the DCN are likely both decidual cells and fetal
mesenchymal cells.
3.2. Localization of DCN in the Uterus and Placenta in the Human and Other Species
DCN is present in both fetal mesenchymal cells and decidua in the human at different
gestational ages [40]. While DCN is an imprinted gene involved in placental development in
mice [50], it is not an imprinted gene for humans [51], pigs [52], and cows [53]. Among cows,
DCN mRNA expression in the endometrial stroma and chorionic mesenchyme increased
during implantation and fell during placentome growth. This drop in DCN was reported
to impact proliferation, migration, and angiogenesis in the placenta [53]. DCN protein
concentration was greater among placentas from parturient cows than first-trimester cows,
with higher levels in the fetal portion at both stages [54]. Another time-dependent property
of DCN is the composition of the GAG chain. During the latter stages of gestation, a
decrease in chondroitin sulfate (CS) and an increase in dermatan sulfate (DS) were noted
in the rat placenta [55]. These trends are reminiscent of the shift from a hybrid of CS and
DS to DS in aging skin, which coincided with decreased flexibility [56]. In the placenta,
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an increase in the ratio of type III to type V collagen was noted, which may aid with
delivery [57]. Thus, this movement from CS to DS could influence the binding of placental
DCN with collagen, inducing flexibility [55].
3.3. Role of DCN in Decidualization during Pregnancy
Decidualization is a process that denotes the transformation of endometrial stromal
cells (fibroblasts) into specialized polygonal-shaped secretory cells, and it is associated with
extensive changes to the extracellular matrix of the uterine stroma. This process has been
extensively studied in humans and rodents. In the human, a minor cyclic decidualization
occurs during the second half of the menstrual cycle, and it can be induced in rodents
artificially after hormone priming [58]. In pregnancy, this process was associated with
uterine gland transformation, uterine natural killer (uNK) cell influx, and spiral artery
remodeling to maintain adequate blood supply to the growing fetus [59]. The levels of
DCN extracted from the uterus was reported to drop during pregnancy until term [60].
The extensive remodeling of uterine ECM that occurs during decidualization has been
associated with changes to DCN distribution. In mice, decidua begins to develop at the time
of blastocyst attachment on gestational day (GD) 4.5 of pregnancy. During the next 3 days
of gestation, decidual cells surrounding the site of embryo attachment proliferate and
differentiate extensively, eventually becoming larger, often with binucleated or polyploid
status [61]. Collagen fibrils with larger diameters up to 250 nm seem to be exclusively
present in the decidualized mice uterine stroma [62,63].
An autocrine role of DCN in maturation of spindle-shaped fibroblast-like endometrial
stromal cells into large polygonal-shaped decidual cells producing insulin-like growth
factor-binding protein (IGFBP-1) and prolactin (PRL)—two well-recognized decidual maturation markers—was shown by Halari et al. (2020) [39]. This was done by knocking out the
DCN gene in human endometrial stromal cells (HESCs) and exposing them to decidualizing stimuli 8-bromo-cyclic AMP and medroxyprogesterone acetate (MPA). The cells failed
to mature as attested by retention of fibroblastic morphology, reduction in polyploidy, and
reduced ability to produce IGFBP1 and PRL. Heart and neural crest derivatives-expressed
protein 2 (HAND2) and progesterone receptor (PGR) were identified as potential downstream mediators of DCN effects. No role of BGN was detectable as evidenced by the
unchanged expression of BGN in DCN-depleted HESC [39].
3.4. Role of DCN in Collagen Fibrillogenesis
The first genetic evidence for the role of DCN in collagen fibrillogenesis was shown
in DCN-null mice. These mice displayed abnormal collagen structure in the dermis and
the skin fragility phenotype [64]. This phenotype is caused by thinning of the dermis
with concurrent reduced tensile strength, a biomechanical impairment directly linked to
the abnormal collagen network. Collagen fibrils in decidualized endometrium of DCN
knockout (Dcn−/− ) mice displayed larger and more heterogenous diameters, as well as
abnormal outlines, compared with wild-type mice [65]. DCN-null mice have tendons
with irregular fiber morphology, abnormal fiber diameter distributions, and atypically
nonuniform interfibrillar spaces [66,67]. These morphological changes have been attributed
to disturbed lateral aggregation of thin fibrils [63]. Thin fibrils, between 10 and 50 nm in
diameter, were present in greater quantities among Dcn−/− mice, suggesting dysregulation
or reduced rate of lateral aggregation [65].
3.5. Roles of DCN in Matrix Remodeling and Structural Stability of Fetal Membranes
Preterm premature rupture of fetal membranes (PPROM), which is responsible for
many preterm births (PTB) [68], has been linked to Ehlers–Danlos syndrome (EDS) [69,70].
A subtype of this syndrome involves a mutation in xylosylprotein-4β-galactosyl-transferase,
which results in the secretion of non-glycosylated abnormal DCN [71,72]. The Dcn−/− mice
resemble the cutaneous defects observed in the EDS, characterized by skin hyperextensibility and tissue fragility [73] in a way opposite to fibrosis. EDS patients also experience
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a heightened risk of aortic rupture [74]. The development of this condition also involves
TGF-β signaling [75].
There appears to exist a functional connection between TGFβ and DCN in the murine
fetal membranes. At gestational day (GD)12 in mouse, TGFβ, Smad-3, and phosphorylated
Smad-3 levels were higher among Dcn−/− fetal membranes than wild-type. Through a
TGFβ-dependent pathway, DCN participates in fetal membrane remodeling during early
gestation by upregulating MMPs and downregulating tissue inhibitors of metalloproteinases (TIMPs) [76]. In the absence of DCN, protein expression of MMP-8 and MMP-9
was lowered, while TIMP-1 and TIMP-2 expression was upregulated [76]. At GD18, Dcn−/−
fetal membranes have similar TGFβ levels to wild-type, but levels of Smad-2 and phosphorylated Smad-2 and Smad-3 are reduced. Independent of TGFβ, DCN acts to stabilize fetal
membranes by lowering MMP activity during late gestation. Moreover, the abnormal ratio
of phosphorylated Smad-2 to Smad in the Dcn−/− fetal membrane mesenchymal cells was
rescued by the addition of a recombinant DCN protein core, but only if the TGFβ receptor
was not blocked [76]. The above results show that DCN regulates the balance between fetal
membrane matrix remodelling and stabilization during gestation.
Vaginal delivery has been associated with weakened fetal membranes [77], which
was not satisfactorily accounted for by decreasing collagen concentration [78]. DCN is
the main proteoglycan in the amnion and closely localized with collagen fibrils [79]. A
decrease in DCN and collagen was observed in the cervical amnion, indicating that the
cervical site is the location of membrane rupture [80]. This finding was consistent with
increased quantities of leukocyte elastase and MMP-9, which degrade collagen and DCN,
in the cervical membranes [78,81,82]. Considering the upregulation of cyclooxygenase
(COX)-2 in term fetal membranes [83], it has been suggested that initiation of labor starts
in the choriodecidual membranes [84]. DCN and collagen were plentiful in the fibroblastic
portion of the chorion [78], with most DCN mRNA localized in decidual cells for the
choriodecidual membranes [84]. DCN transcription in the choriodecidual membranes
was greater after term vaginal delivery than preterm delivery but lower than before labor.
Scarce DCN expression after preterm labor suggests that DCN does not simply maintain
uterine quiescence [84].
3.6. Role of DCN in Uterine Cervix and Myometrium
As a prerequisite for standard vaginal delivery, cervical ripening involves softening,
effacement, and dilation. This process involves a slow phase from early gestation to term
and a rapid phase around early labor. DCN may promote cervical softening and dilation as
observed in term pregnant cervices in which the synthesis and levels of DCN increased [85].
Conversely, a consistent rise in cervical DCN expression was noted in rats, with excess
DCN disrupting collagen organization and supposedly weakening the tissue [86].
Myometrial DCN expression was elevated at term for humans [84] and after spontaneous term and betamethasone-induced premature labor for ewes. This rise in DCN
may aid in matrix alterations critical for myometrial activation, with a possible connection
between DCN expression and myometrial contractibility [87]. Changes in myometrial DCN
expression during gestation may suggest an underlying regulatory framework heavily
dependent on ovarian hormones. Among nonpregnant ovariectomized ewes, a significant
rise in myometrial DCN mRNA concentration was only noted after estradiol (E2) treatment,
which was not antagonized by progesterone [87]. Furthermore, DCN distribution within
the mouse myometrium was primarily influenced by E2 [88].
3.7. Role of DCN in Murine Endometrium
In mice, DCN is found in the endometrial stroma even before decidualization. Martin
et al. showed that DCN expression was higher in the myometrium during the preimplantation phase and, surprisingly, endometrial localization of DCN was altered with the
GD of pregnancy [89]. They observed high DCN expression in the endometrium on GD1
(preimplantation) and DCN loss in the endometrial stroma post implantation on day 5.
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Since DCN has an antiproliferative property, its loss during the transition of stromal cells to
decidual cells might be functionally important [90]. Another study confirmed the presence
of DCN in the endometrium even on GD18 of mouse pregnancy [91]. This may indicate
that DCN reappears again later in pregnancy, and the change in DCN expression is likely
to have a functional significance.
Systemic DCN-knockout mice succumb to skin fragility due to disorganized collagen
fibers in the dermis layer of skin owing to the need for DCN in collagen assembly [64].
They are fertile but show an upregulation of related proteoglycans including BGN and
lumican in the uterus [65]. DCN/BGN dual knockout mice exhibit reduced litter size,
early pregnancy loss [92], and loss of uterine tissue function in a DCN dose-dependent
manner [91]. However, these studies did not test whether DCN is critical for decidual
development, as shown for maturation of HESC into decidual cells in the human [39].
3.8. Role of DCN in Human Endometrium
The human endometrium undergoes extensive remodeling in preparation for implantation [93]. In stromal cell cultures representative of the human proliferative and
secretory human endometrium, DCN expression was higher in the stromal areas than in
the epithelia [94,95]. Deficient levels of DCN were found in the normal proliferative phase
endometrium, with a reported drop during the secretory phase and a more remarkable fall
during menopause [96]. Upregulation of DCN mRNA was observed after proliferative human endometrium cell cultures were incubated with E2 [95]. Likewise, uterine DCN mRNA
levels rose among ovariectomized mice treated with either E2 or MPA. Only E2 treatment
allowed for the deposition of DCN in the superficial stroma of the endometrium [88].
DCN was found to be produced by decidual cells, colocalized with TGFβ in the decidual ECM throughout human gestation [40]. During uterine decidualization, upregulation of
human PRL and its receptor (PRLR) was reported [97,98], alongside DCN mRNA. However,
PRL limited the rise of DCN in decidualized human uterine fibroblast cells, suggesting
that PRL acts in an autocrine capacity to inhibit differentiation [98]. In view of the need of
DCN for decidual cell maturation, shown earlier [39], these findings suggest a complex
regulatory network in decidual development.
4. Distribution and Functions of BGN in the Pregnant Uterus and the Placenta
4.1. Roles of BGN in Collagen Fibrillogenesis in the Uterus
Mice lacking both DCN and BGN produce abnormal collagen fibrils, characterized by
uncontrolled lateral fibril assembly, which in turn results in fibrils with enormous diameters
and aberrant profiles [64,99–101]. BGN can regulate collagen fibrillogenesis in vivo (cornea,
tendon) and in vitro, compensating for the loss of DCN [67,102]. An increased expression of
BGN in the non-decidualized endometrium has been observed in DCN-null mice. In these
mice, collagen fibrils undergo substantial structural change such as an increase in diameter
and the appearance of an irregular profile [65]. BGN displayed similar localization in
decidualized tissue for both Dcn−/− and wild-type mice [65]. Like DCN, it seems that BGN
influences collagen fibrillogenesis in the uterine stroma. Thus, in mice, DCN functions can
be compensated for by BGN.
4.2. Roles of BGN in Matrix Remodeling and Stabilizing the Fetal Membranes
BGN knockout (Bgn−/− ) mice were used to investigate its potential impact on fetal
membranes [76]. At GD12, Bgn−/− fetal membranes displayed similar levels of TGFβ,
Smad-2 and 3, and their phosphorylated counterparts, as noted in the wild-type mouse.
BGN promotes MMP activity in fetal membrane remodeling independent of TGFβ during
early gestation. At GD18, TGFβ and Smad-2 levels decreased among Bgn−/− fetal membranes compared with wild-type. Through a TGFβ-dependent pathway, BGN works to
upregulate TIMPs and collagen α1VI for fetal membrane stabilization in late gestation [5].
Like DCN, the regulation exerted by BGN over fetal membrane matrix is biphasic. In the
Bgn−/− /Dcn−/− double-null mice, the expression of TIMP-3, TIMP-4, and collagen α1VI
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was reduced. While these two SLRPs have complementary roles during gestation, they
have distinct effects on TIMPs, MMPs, and collagen α1VI [76].
Changes in BGN may be involved in the modified biomechanical properties of the
human fetal membranes. While not the main proteoglycan in term amnions, BGN was
mainly located around and within the amniotic epithelium [79]. In the pre-labor amnion,
the levels of BGN in the mid-zone region were greater than the cervical region. However,
BGN concentration doubled after delivery in the cervical amnion, further supporting it
as the site of membrane rupture [80]. BGN was the predominant proteoglycan in the
trophoblastic portion of the chorions and the midzone region of the pre-labor choriodecidua. A significant increase in the BGN concentration within the mid-zone choriodecidua was noted after delivery, which could account for the heightened extensibility [77].
These findings strongly suggest that BGN contributes to preparing the fetal membranes for
labor [79,80].
4.3. Role of BGN in the Uterine Cervix, Myometrium, and Endometrium
Functional roles of BGN present in the uterine cervix and myometrium remain largely
unexplored. In the human uterine cervix, inconsistent findings on BGN synthesis and levels
have been reported. While one study documented a rise in postpartum cervices [85], an
in vitro study reported a drop in BGN levels in fibroblasts from preterm and term partum
cervix [103]. These disparities may be accounted for by the nature of degradation and the
number of side chains in BGN core protein [103]. In the mouse myometrium, BGN was
not expressed in the absence of ovarian hormones. However, BGN was detected in both
the external and internal muscle layers and the connective tissue between the layers after
treatment with E2 or MPA [88].
DCN was the dominating proteoglycan in the human uterus, and a smaller amount
of BGN was found. A considerable amount of heparan sulfate proteoglycans were also
detected. DCN and BGN decreased by 40% until term. The amount of heparan sulfate
proteoglycans increased by 46% during active labor. These data indicate that a considerable
remodeling of the uterine connective tissue occurs during pregnancy and labor. It is speculated that these changes in the proteoglycans may be important for normal myometrial
contractions during labor [60].
Prior to decidualization, BGN was mainly absent from the mouse endometrial stroma
but was widely present in the decidual and non-decidualized regions after decidualization [89,104]. The increase in BGN expression may be required to form the appropriate decidual collagen organization [89]. BGN was downregulated in the secretory phase [96,105],
with a more remarkable fall in menopause endometrial tissue [96]. In support of the role
of ovarian hormones, BGN expression in ovariectomized mice rose after administration
with MPA but not E2 alone. It was also suggested that the deposition of the BGN protein
was dependent on E2 [88]. The nonpregnant premenopausal uterus is subject to cyclic
structural changes. Using immunohistochemistry, Lucariello et al. (2015) [96] showed that
the distribution patterns of SLRPs were completely modified in the pathological compared
to normal endometrium. The expression of SLRPs was low/absent in all endometrial
pathologies examined compared to normal endometrium. There was an increase in lumican from the proliferative to secretory phase of the endometrium and a decrease in
fibromodulin, BGN, and DCN. In menopause endometrial tissue, the level of expression of
fibromodulin, BGN, DCN, and lumican dramatically decreased. The results revealed the
prominence and importance of proteoglycans in the tissue architecture and extracellular
matrix organization.
4.4. Role of BGN in Endometrial Decidualization
Studies by San Martin et al. [106], using immunocytochemical electron microscopy,
showed that BGN is associated with the presence of thick collagen fibrils in decidualized
regions of the endometrium, and that DCN is associated exclusively with thin collagen
fibrils in non-decidualized endometrial areas. These results strongly indicate that BGN
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plays a role in collagen fibrillogenesis and probably participates in the determination of
collagen fibril thickness in the mouse decidua. No functional study of BGN in human or
murine decidual tissue has been reported to our knowledge (Table 2).
Table 2. Distribution and functions of DCN and BGN in the pregnant uterus and placenta.
SLRP

Distribution

Function

Mode of
Action

Restraining trophoblast
invasion, migration,
invasiveness, and
endovascular
differentiation

EGFR, IGFR-1,
and VEGF-2

Decidual cell maturation

HAND2 and
PGR

Mice

Collagen fibrillogenesis

Collagen

Human

Restraining trophoblast
stem cell self-renewal and
differentiation

Cow

Restraining proliferation,
migration, and
angiogenesis

Rat

Inducing flexibility

Species

Human
Decidua

DCN

Decidua/placenta
(fetal
mesenchyme)
Placenta (fetal
mesenchyme)

Human
Fetal
membranes

Cervix

Mice
Human

Collagen
N/A

Matrix remodeling and
structural stability

Collagen organization

TGFβ, Smad,
MMPs, and
TIMPs
Collagen

Rat

Myometrium

Ewe

Myometrial activation

Endometrium

Human

Matrix remodeling during
the menstrual cycle

N/A *

Decidua

Mice

Collagen fibrillogenesis

Collagen

Human
BGN

N/A *

N/A *
Matrix remodeling and
structural stability

Fetal
membranes

Mice

Cervix

Human

Myometrium

Mouse

N/A *

Human

Matrix and tissue
organization during the
menstrual cycle

Endometrium

Rhesus
monkey

Fetal memDCN/BGN branes/placenta
Mice
Uterus
* N/A: not known at present.

Collagen organization

TGFβ, Smad,
MMPs, and
TIMPs
Collagen

N/A *

Achievement of term
gestation, with
compensatory
upregulation
Uterine function during
parturition, with partial
compensation of DCN by
BGN

TGFβ
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5. Mode of Action of DCN
DCN binds to many constituents of the ECM, growth factors, cell surface tyrosine
kinase receptors, and Toll-like receptors, leading to a multiplicity of DCN actions.
(a) Collagen: Interaction between the DCN core protein and collagen is needed for
collagen fibrillogenesis [107,108], increased fibril diameter [107], and increased tensile
strength of fibers [109,110]. As mentioned earlier, the presence of DCN was associated with
altered collagen organization in the cervix [85,86], uterus [65,89], fetal membranes [76,79,80],
and placenta [55].
(b) DCN interaction with thrombospondin-1 (TSP-1) [111,112] and fibronectin
(FN) [113,114] may impede migration of endothelial cells and contribute its antiangiogenic action. DCN-mediated inhibition of VEGF-mediated angiogenesis results from DCN
binding to VEGFR2 [45].
(c) Growth factors: The core protein of DCN interacts with TGFβ, with two identified
binding sites of different affinities [115]. While DCN was linked to TGFβ inactivation for
reduced cell growth [116], it has been alternatively proposed that TGFβ sequesters DCN in
the ECM [117]. DCN was also associated with limiting TGFβ-dependent fibrosis [118,119].
We demonstrated that TGFβ was detected in the cytoplasm of the villous syncytiotrophoblast throughout gestation. In the decidual tissue, TGFβ distribution switched from
mainly being present in the ECM during the first trimester to intracellular in the decidual
cells at term. Given the colocalization of DCN with TGFβ in the first-trimester decidua, we
proposed that DCN stores TGFβ to inhibit its antiproliferative and anti-invasive actions.
Furthermore, matrix-degrading enzymes secreted from invasive trophoblasts could break
up this complex to activate TGFβ [40]. The finding that TGFβ bound by DCN is released
after cleavage mediated by MMP-2, -3, and -7 [120] supported our proposed mechanism
for controlling EVT invasion. However, we discovered that DCN diminished proliferation,
inhibition, and migration of EVT cells independently of TGFβ in vitro and in situ [42,43].
The antiproliferative effect of DCN was associated with p21 upregulation. We also determined that malignant trophoblast (choriocarcinoma) cells resisted the negative regulation
of proliferation, migration, and inhibition exerted by decidua-derived TGFβ or DCN [42].
The underlying mechanisms remain to be explored.
(d) Tyrosine kinase receptors (TKR): DCN can bind as an antagonistic ligand to
multiple TKRs to exert negative regulatory functions such as proliferation, migration, and
invasiveness of human EVT cells [43,48]. As a ligand for EGFR [121,122], DCN prolongs
p21 production [123] and promotes caveolar-mediated endocytosis of EGFR [124] for
reduced proliferation [125] of cancer cells. While DCN binding to IGF-IR resulted in
greater phosphorylation, it also interacted with IGF-1 [126]. The DCN core protein also
induced transient phosphorylation and degradation of the MET receptor [127], which
downregulated hypoxia-inducible factor 1 α (HIF-1α) and β-catenin. While this interaction
reduced transcription of VEGFA, MMP2, and MMP9, it increased TSP-1 and TIMP3 for
an overall antiangiogenic effect [128]. Furthermore, DCN can inhibit VEGF-induced
angiogenesis [129]. Our lab uncovered the binding of the DCN core protein to VEGFR-2,
overlapping with its ligand-binding site for VEGF-E and VEGF-A with a lower affinity
than its normal ligands. This low-affinity interaction inhibited VEGF-E-induced migration
of EVT cells by blocking extracellular signal-regulated kinase (ERK) 1/2 activation [44].
Later work revealed that DCN inhibited VEGF-mediated endovascular differentiation and
migration in EVT cells by interfering with p38 mitogen-activated protein kinase (MAPK)
and ERK1/2 pathways in parallel [45].
(e) Toll like receptors (TLR): As a ligand for the Toll-like receptors 2 and 4 (TLR2/4) in
mouse macrophages, DCN increased the expression of proinflammatory tumor necrosis
factor α (TNFα), interleukin (IL)-12, and anti-inflammatory IL-10 through MAPK and
nuclear factor-κB (NF-κB) pathways. By binding to and inactivating TGFβ, DCN could
also curtail IL-10 abundance [130]. Substantial thrombin inhibition involving heparin
cofactor II (HC II) was reported in pregnant women. This elevated anticoagulant activity
was attributed to a DS proteoglycan [131], later identified as DCN in the human term
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placenta [132]. Both of these interactions may account for proposed roles of DCN in immune
signaling [133,134] and blocking thrombosis [135] involving several abnormal pregnancies.
6. Mode of Action of BGN
Like DCN, BGN binds to constituents of ECM, growth factors, and TLRs but not TKRs.
(a) Collagen: Like DCN, BGN interactions with collagen are proposed to modulate
ECM organization. While a lower amount of collagen was incorporated into fibrils in the
presence of BGN, no changes in fibril diameter were associated with BGN treatment [107].
These interactions with collagen have widespread implications for cervix ripening [85],
decidualization [65,89], and fetal membrane rupture [80].
(b) Growth factors: TGFβ binds to the core protein of BGN with similar affinity and
binding sites as DCN [115]. This interaction may impact the TGFβ–bone morphogenetic
protein (BMP)–Smad pathway and its crosstalk with the pathway involving Wnt and Wnt-1induced secreted protein (WISP) [92,136]. The proposed anticoagulant activity of BGN [131]
was reaffirmed by BGN promoting thrombin inhibition by HC II [137]. Dysregulation in
the above pathways may account for proposed impact of BGN in abnormal pregnancies.
(c) TLRs: As an endogenous ligand of TLR2/4 in macrophages, BGN plays a multifaceted role in inflammation. BGN binding to TLR2/4 activated p38, ERK, and NF-κB
signaling, which resulted in a rise in TNFα and macrophage inflammatory protein-2 (MIP2) levels [138]. TLR2/4-BGN binding was also associated with a rise in C–X–C motif
chemokine ligand (CXCL)-1, CXCL2, CXCL13, C–C motif chemokine ligand (CCL)-2, and
CCL5 [139–141]. Intriguingly, the interaction between TLR2/4 and BGN also upregulated HIF-1α and VEGF in endothelial cells [142]. BGN binds to TLR2/4 and purinergic
P2X4/P2X7, which activated the nucleotide-binding oligomerization-like receptor, pyrin
domain-containing 3 (NLRP3) inflammasome and enhanced the release of mature IL1β [143]. Through complex interactions involving TLR2/4 and NADPH oxidases (NOX),
BGN influenced the synthesis and maturation of IL-1β [144]. The proinflammatory role
of BGN deserves investigation, when considering the impact of inflammation in pregnancy [133,145].
(d) TKRs: Unlike DCN, many BGN functions do not appear to be mediated through
interactions with TKRs. For example, unlike DCN, BGN did not affect proliferation and
expression of p21 through EGFR signaling [123]. However, the interaction between BGN
and TGFα was reported to disrupt downstream EGFR signaling, which hindered the
migration of mesenchymal cells during eyelid morphogenesis [146]. While the interaction
between VEGFA and BGN did not directly activate VEGFR signaling, the reportedly
proangiogenic BGN may result from the matrix storage of VEGF [147].
7. Role of DCN in Pregnancy-Associated Disorders
7.1. Preeclampsia
PE is considered to be the maternal consequence of impaired remodeling of uterine
arteries, which is highly dependent on the action of EVT cells. While some investigators
reported that DCN was upregulated among PE placentas [148,149], others have concluded
that no such difference exists [150]. This disparity may be explained by the extent of decidual tissue included in placental samples. Our lab demonstrated that DCN overexpression
in PE was selectively noted in the decidual and not in the chorionic villus mesenchymal
cells [47].
PE can be further classified by onset, with early-onset (EOS) PE before the 34th
gestational week and late-onset (LOS) PE at the 34th gestational week or later [151]. DCN
placental levels were substantially greater in EOS-PE patients than those with LOS-PE [148].
It has been noted that serum DCN levels were higher among PE women during the third
trimester [150].
Our lab determined that PE patients had higher plasma DCN levels, including free
and fibrinogen-bound DCN, during the second trimester. This alteration existed before
the clinical onset of PE, pointing to its promise as a predictive biomarker. Since maternal
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body mass index (BMI) and body weight do not impact the size of the placenta, the inverse
correlation between DCN and these markers does support the decidua as the primary
source of plasma decorin during pregnancy [47]. More specifically, DCN mRNA and
protein levels were greater among basal plate decidual cells from PE placentas at all stages,
with these differences not observed in the villus mesenchymal cells or chorionic villi. These
results demonstrate that high DCN levels at the fetal–maternal interface contribute to PE
development and reaffirm the maternal origin of this disease [47].
Knocking down DCN in HESCs led to the incomplete restoration of EVT cell invasiveness of stromal cells. This established a causal link between high DCN levels and
the hypoinvasive EVT phenotype [47]. These findings are consistent with earlier work
showing that overexpression of DCN reduced EVT migratory and invasive capacity along
with a decrease in MMP-2 and MMP-9 protein levels [149]. This negative regulation of
trophoblast migration and invasion by DCN contributes to the insufficient conversion
of maternal spiral arteries [149]. Trophoblast cells overexpressing DCN also experienced
decreased proliferation, with cell-cycle arrest occurring at the G1–G0 phase and enhanced
apoptosis [149].
7.2. Fetal Growth Restriction
FGR occurs when the fetus does not accomplish its in utero growth potential and is
often assigned when the birth weight falls at or below the 10th percentile for the fetus’s
gestational age and gender. As the fetal consequence of incomplete remodeling of the
uterine arteries, one might expect the SLRP trends from PE to also apply to FGR patients.
Idiopathic FGR patients were reported to have higher maternal DCN serum levels, which
were negatively correlated with birth weight [152]. In contradiction, lowered DCN mRNA
and protein expression was detected for idiopathic FGR placentae [153] and primary
placental microvascular endothelial cells (PLECs) from FGR pregnancies [135]. Small for
gestational age (SGA), which refers to birth weight below the 10th percentile, is often
used as a surrogate for FGR [154]. The above placental trend was further supported by
lower expression of DCN mRNA and protein among first-trimester SGA placentae [155].
Evidently, further work is needed to resolve the discrepancy in these reports. In our studies,
we found that a subset of FGR was associated with high DCN expression in the decidua
only in the presence of PE [47].
In the placenta, DCN protein was localized to the microvascular endothelial cells of
villous stroma around fetal capillaries [153]. When DCN mRNA and protein expression
was reduced in human microvascular endothelial cells (HMVEC) by SiRNA treatment,
the cells exhibited impaired vascular network formation in vitro and displayed increased
endogenous thrombin levels and decreased proliferation without a rise in apoptosis [135].
These results were corroborated with PLECs from FGR pregnancies [135]. These findings
contradict the well-recognized antiangiogenic function of DCN [21,44,45,48]. It remains a
mystery whether these results were specific for the particular endothelial cell class used or
are VEGF-independent. VEGF is the major angiogenic factor acting by binding to VEGFR-2,
and DCN was shown to act as a negative regulatory ligand by binding to VEGFR-2 [44,45].
In PE patients, DCN core proteins were upregulated in the umbilical arteries (UA) [156],
which may be related to increased collagen [157], and umbilical veins (UV) of PE patients [158]. These changes in DCN expression may impact the mechanical properties
of umbilical vessels along with fetal blood circulation [156,158]. While the expression of
collagen types I and III was higher in UAs from FGR pregnancies, differences in DCN
mRNA levels were not uncovered [159]. Despite the absence of disparities in UA and
UV DCN levels associated with idiopathic FGR, meaningful correlations between these
quantities were established with UA systolic/diastolic ratio, UA refractive index, and
median uterine artery refractive index [152].

Int. J. Mol. Sci. 2021, 22, 10584

16 of 25

7.3. Preterm Birth, Preterm Labor, and PPROM
DCN protein concentrations in the fetal membranes dropped at term, with a further
fall after labor (both preterm and term) within the amnion. This decline in DCN during
the third trimester and labor may aid in mechanical weakening [160]. Consistent with
this finding, preterm labor patients displayed lower serum DCN levels. While serum
DCN levels alone could predict PTB before 37th gestational week among preterm labor
patients, a combined measurement with cervical length was required to predict PTB within
7 days and before the 34th gestational week [161]. PPROM was associated with lower
DCN serum levels appearing in the second trimester [145] and a decline in p-Smad-2 [134].
As a possible cause of PPROM [68,162,163], chorioamnionitis was linked to substantial
DCN degradation in the amnion [160]. Only in the presence of infection was lower fetal
membrane DCN protein expression noted for PTB with PPROM than without PPROM [134].
Inflammation-induced degradation or downregulation of DCN may account for weakened
fetal membranes in PPROM pregnancies [134,160].
7.4. Endometrium-Related Disorders
DCN has been associated with regulating endometrial organization where its expression decreases from proliferative to secretory phase and is also reduced in endometrial
pathologies such as hyperplastic and postmenopausal polyp [96]. Endometrial hyperplasia is common among polycystic ovary syndrome (PCOS) patients, which display
greater DCN protein expression in their proliferative phase of endometrial tissue. This
phenomenon has been accounted for by excessive estrogenic activity [164]. Endometriosis,
which refers to the presence of endometrium-like tissue outside the uterine cavity, can be
treated with dienogest, an effective progestin that reduces endometriotic lesions [165–167].
Administration of this drug or progesterone in human endometrial epithelial and stromal
cells increased DCN mRNA expression by promoting progesterone binding to the DCN
promoters, verified with dienogest-treated endometriosis patients [168].
7.5. Invasive Placentas
An abnormally invasive placenta is a property shared by placenta accrete, percreta, invasive moles, and choriocarcinomas. DCN was detected in EVT cells for the above pathologies suggesting that this DCN is a marker for hyperinvasive placentas [169]. Since DCN is
a product of mesenchymal cells, this unexpected finding may suggest that trophoblast cells
in these hyperinvasive placentas may have undergone epithelial–mesenchymal transition
(EMT), a possibility that needs confirmation. Another possibility suggested by the authors
is that DCN is a pro-invasive molecule, which has been refuted by many studies showing its anti-invasive function in trophoblast cells [41,149], upregulation in PE-associated
decidua [47], and tumor-suppressive function when upregulated in tumor-stroma [170].
Al-Khan et al. (2020) [171] examined hyperglycosylated hCG (h-hCG), decorin, and IL-8
in the maternal plasma from five groups, comprising (1) normal term controls, (2) placenta previa controls, and cases of (3) placenta increta/percreta without placenta previa,
(4) placenta previa increta/percreta, and (5) placenta previa accrete; they found no significant differences of these markers in the various PAS groups from the control groups.
8. Roles of BGN in Pregnancy-Associated Disorders
8.1. FGR
The placentae of third-trimester idiopathic FGR pregnancies were associated with
lower BGN mRNA and protein expression [172], reconfirmed in first-trimester SGA placental tissues [173]. It has been proposed that lowered placental BGN levels may contribute
to FGR by promoting thrombosis or structural alterations [172]. Within the placenta,
BGN protein expression was localized to endothelial cells and subendothelial cells of
the perivascular region of fetal capillaries [172]. Interestingly, reduced BGN expression
in telomerase-immortalized microvascular endothelial cells did not meaningfully affect
apoptosis, proliferation, or thrombin generation [173]. However, these conditions nega-
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tively regulate angiogenic activities, suggesting that BGN is proangiogenic. Furthermore,
substantial shifts in mRNA expression were noted in genes related to angiogenesis, with
some of these trends reaffirmed in SGA first trimester placental villi [173].
8.2. PPROM, PTL, and Endometrial-Related Pathologies
Patients diagnosed with PPROM displayed heightened BGN serum levels during the
second trimester, which may represent an immune response to early tissue damage in
the fetal membranes [145]. Chorioamnionitis was associated with substantial degradation
of BGN, which may account for diminished strength of preterm fetal membranes [160].
While BGN concentration was lower in the preterm amnion, BGN expression was primarily
unchanged between the preterm and term chorio-decidua [160]. Both term and preterm
labor were associated with increased BGN concentrations in the amnion, which was also
connected to mechanical weakening [160]. In endometrial pathologies, BGN expression
was lowered in hyperplasias and postmenopausal polyps [96], but a rise was noted in
PCOS endometrium [164]. Like DCN, it has been suggested that BGN regulates tissue
organization [96].
9. Compensatory and Functional Overlaps of DCN and BGN
The uterus remains dormant during gestation to prevent PTB and undergoes active
contraction for the expulsion of the fetus [174], with EDS women at increased risk of uterine
rupture [175,176]. Knockout of both DCN and BGN in mice was associated with a heightened risk of dystocia and delayed labor onset, which may be underreported in EDS women
due to their widespread prevalence and easy treatment [91]. While uterine tissue failure
was dependent primarily on DCN, a fall in spontaneous uterine contractile amplitude and
oxytocin-induced contractile force was noted in the absence of either SLRP [91]. TGFβ was
downregulated in the BGN-null uterus, suggesting its role in BGN-mediated regulation
of uterine muscle. There was insufficient evidence for compensation between DCN and
BGN on a transcriptional or protein level in the uterus. Overall, the Bgn−/− /Dcn−/− mouse
presents a good model for testing treatments for human dystocia [91].
Among female mice carrying wild-type and null alleles of DCN/BGN, the risk of
PTB was inversely related to the number of wild-type DCN and BGN alleles per genotype. Decreased expression of both DCN and BGN was associated with increased risk
of PTB, which was protected against by the presence of at least two wild-type SLRP alleles. Fewer offspring with the Bgn−/− /Dcn−/− genotype than anticipated were found
after birth [92]. While mouse placental DCN and BGN protein levels were upregulated
in each other’s absence, compensation likely occurs after post-transcriptional processes
in the placenta. While the same was not reported in the mouse fetal membranes [92], a
later study uncovered transcriptional compensation only in the absence of inflammation.
This loss of compensation due to the absence of these SLRPs shortened the time between
infection and PTB [133]. Consistent with other studies [91], the differential impact of these
SLRPs on MMP-8 and collagen α1VI levels during inflammation [133] and differences in
developmental regulation [92] suggest that the two SLRPs work through distinct pathways.
10. Conclusions
Decidua-derived DCN plays important paracrine roles in trophoblast stem-cell renewal, differentiation, migration, and invasiveness in normal pregnancy, and its overproduction is associated with PE. The inhibitory roles of DCN in vascular endothelial cells
explain the angiostatic functions of DCN in PE. The roles of DCN in maturation of fetal
membranes by virtue of promoting collagen fibrillogenesis explain the association of DCN
mutations with PPROM, a feature of EDS. BGN appears to play a minor compensatory role
in some of these pathologies such as PPROM.
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Unanswered Questions
(1) More research in needed to examine whether an elevation of plasma DCN is a
predictive biomarker of PE and a subset of FGR in ethnic groups other than Caucasian
(such as African American, North American indigenous, Indo-Aryan, and Indo-Dravidian)
populations. (2) DCN fragments (peptides belonging to LLR5 domain) were shown to be
anti-angiogenic [129] and migration-inhibitory for EVT cells [44]. Whether these peptides
are predictive biomarkers for preeclampsia remains to be investigated. Biological functions
of matricryptic fragments from other SLRPs in the placenta remain an open area for future
studies. (3) While DCN has been shown to act as an inhibitory ligand by binding to
several TKRs such as EGFR, IGFR-1, VEGFR-2, and MET, the possibility of DCN action by
binding to other TKRs (such as platelet-derived growth factor receptor (PDGFR), HER2,
ROS1, ALK, and RET) needs to be examined. (4) Possible functions of BGN in human or
murine decidual cells need be explored by knocking out BGN in ESCs. (5) The functional
significance of DCN expression in hyper-invasive placental trophoblast remains to be
explored. (6) The molecular mechanisms of resistance of choriocarcinoma cells to invasionrestraining functions of DCN need to be examined.
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